ClinicalTrials.gg
RecruitingNCT07225985Updated May 11, 2026

Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

A Phase 1/2 interventional study of Bendamustine and Pralatrexate in Recurrent T-Cell Non-Hodgkin Lymphoma and Refractory T-Cell Non-Hodgkin Lymphoma, sponsored by Fred Hutchinson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by Fred Hutchinson Cancer Center · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing pralatrexate in Lymphoma, T-Cell — 2 open to participants now, 4 under way, none of them phase 3. pralatrexate · Lymphoma, T-Cell.

Planned enrollment
6th of 10
50 · median 53
Started
2026
the only one that year
Phase 1/2
4 of 10
1 open now
Registered
9th of 10
by date
Lead sponsor
1 of 10
Fred Hutchinson Cancer Center

Among the 10 studies testing pralatrexate in Lymphoma, T-Cell, this one is the 6th largest by planned enrollment, is the only one that started in 2026, is one of 4 in phase 1/2, and was the 9th registered.

Lymphoma, T-Cell

310 studies on the registry are indexed under Lymphoma, T-Cell; 76 are open to participants now.

Browse Lymphoma, T-Cell studies →

Open to participants now

2 of the 10 studies testing pralatrexate in Lymphoma, T-Cell are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About pralatrexate

pralatrexate: first FDA approval 2009 (FOLOTYN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Lymphoma, T-Cell studies recruiting now, 40 (61%) set no upper age limit and 20 (30%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing pralatrexate in Lymphoma, T-Cell, or all of them as a file.
02

Study summary

This phase I/II trial studies the side effects and best dose of pralatrexate in combination with bendamustine and total-body irradiation (TBI) followed by a donor stem cell transplant in treating patients with T-cell non-Hodgkin lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Pralatrexate may block the growth of cancer cells and cause them to die. It is a type of dihydrofolate reductase (DHFR) inhibitor. Bendamustine may damage the DNA in cancer cells and cause them to die. It is a type of alkylating agent and a type of antimetabolite. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. TBI is a type of radiation therapy that is given to the entire body. Giving pralatrexate with bendamustine and TBI before a donor stem cell transplant may help kill cancer cells in the body and help make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow.

Read the detailed description

OUTLINE:

This is a phase I dose-escalation study of pralatrexate in combination with bendamustine and TBI followed by a phase II expansion study.

Patients receive pralatrexate intravenously (IV) over 3-5 minutes on day -6, bendamustine IV over 60 minutes on days -5, -4, and -3, and TBI on day -1 or 0. Patients then undergo peripheral blood stem cell (PBSC) HCT on day 0. Patients also undergo echocardiography (ECHO) or multi-gated acquisition scan (MUGA) and lumbar puncture during screening, positron emission tomography-computed tomography (PET-CT), magnetic resonance imaging (MRI), bone marrow biopsy/aspiration, and blood sample collection throughout the study. In addition, patients may undergo chest X-rays as clinically indicated.

After completion of study treatment, patients are followed up at 6 and 9 months and at 1, 1.5 and 2 years.

03

Conditions studied

  • Recurrent T-Cell Non-Hodgkin Lymphoma
  • Refractory T-Cell Non-Hodgkin Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years with an HCT-Comorbidity Index (CI) ≤ 5 for patients over 60 years
  • T-cell non-Hodgkin lymphoma (T-NHL) (2022 World Health Organization [WHO] criteria) including primary cutaneous T-NHL that is in untreated or unsuccessfully treated first or subsequent relapse. Patients in morphologic remission (i.e. \< 5% blasts in the bone marrow, if involved) but evidence of minimal residual disease (MRD) by positron emission tomography-computed tomography (PET-CT), multiparameter flow cytometry, cytogenetics/fluorescence in situ hybridization (FISH), or molecular means will be eligible for trial participation
  • The use of bridging chemotherapy prior to initiation of study treatment is allowed. Patients with symptoms/signs of hyperleukocytosis, white blood cells (WBC) > 100,000/µL, or with concern for other complications of high tumor burden of high tumor dynamics (e.g. disseminated intravascular coagulation) can be treated with leukapheresis or may receive a cycle of salvage chemotherapy prior to start of study treatment
  • score ≥ 70; (ECOG) 0-1
  • Adequate cardiac function defined as absence of decompensated congestive heart failure and/or uncontrolled arrhythmia and ≥ 45%
  • ≤ 2.5 x institutional unless elevation is thought to be due to hepatic infiltration by lymphoma, Gilbert's syndrome, or hemolysis
  • Adequate pulmonary function defined as absence of oxygen (O2) requirements and either diffusion capacity of the lung for carbon monoxide (DLCO) corrected ≥ 70%mmHg or DLCO corrected 60-69%mmHg and partial pressure of oxygen (pO2) ≥ 70mmHg
  • ≥ 60 mL/min
  • Prior HCT is permissible if relapse occurred > 6 months after HCT
  • An human leukocyte antigen (HLA)-matched sibling/unrelated donor, mismatched unrelated donor or haploidentical donor for collection of stimulated peripheral blood stem cells must be identified and readily available
  • If the patient has received pralatrexate or bendamustine before and has been sensitive to this regimen, defined as MRD negative complete response (CR) immediately after receiving the treatment and which lasts ≥ 1 year, eligibility will be determined on a case-by-case basis by the study principal investigator (PI)
  • Ability to understand and sign a written document (or legal representative)
  • RELATED DONOR: Related to the patient and genotypically or phenotypically identical for HLA-A, B, C, DRB1 and DQB1. Phenotypic identity must be confirmed by high-resolution typing
  • MATCHED UNRELATED DONOR: Matched for HLA-A, B, C, DRB1 and DQB1 by high resolution typing; OR
  • MATCHED UNRELATED DONOR: Mismatched for a single allele without antigen mismatching at HLA-A, B, or C as defined by high resolution typing but otherwise matched for HLA-A, B, C, DRB1 and DQB1 by high resolution typing
  • MATCHED UNRELATED DONOR: Donors are excluded when preexisting immunoreactivity is identified that would jeopardize donor hematopoietic cell engraftment. The recommended procedure for patients with 10 of 10 HLA allele level (phenotypic) match is to obtain panel reactive antibody (PRA) screens to class I and class II antigens for all patients before HCT. If the PRA shows > 10% activity, then flow cytometric or B and T cell cytotoxic cross matches should be obtained. The donor should be excluded if any of the cytotoxic cross match assays are positive. For those patients with an HLA Class I allele mismatch, flow cytometric or B and T cell cytotoxic cross matches should be obtained regardless of the PRA results. A positive anti-donor cytotoxic crossmatch is an absolute donor exclusion.
  • MATCHED UNRELATED DONOR: Patient and donor pairs homozygous at a mismatched allele in the graft rejection vector are considered a two-allele mismatch, i.e., the patient is A*0101 and the donor is A*0102, and this type of mismatch is not allowed.
  • MISMATCHED UNRELATED DONOR: HLA-matching must be based on results of high resolution typing at HLA-A, -B, -C, -DRB1, and -DQ
  • MISMATCHED UNRELATED DONOR: Mismatch for one HLA class I antigen with or without an additional mismatch for one HLA-class I allele but matched for HLA-DRB1 and HLA-DQ
  • MISMATCHED UNRELATED DONOR: Mismatched for two HLA class I alleles but matched for HLA-DRB1 and HLA-DQ
  • MISMATCHED UNRELATED DONOR: HLA class I HLA-A, -B, -C allele matched donors allowing for any one or two DRB1 and/or DQB1 antigen/allele mismatch
  • MISMATCHED UNRELATED DONOR: If the patient is homozygous at the mismatch HLA class I locus or II locus, the donor must be heterozygous at that locus and one allele must match the patient (i.e., patient is homozygous A*01:01 and donor is heterozygous A*01:01, A*02:01). This mismatch will be considered a one-antigen mismatch for rejection only
  • HAPLOIDENTICAL DONOR: Donors must be haploidentical relatives of the patients. Donor-recipient compatibility will be tested through HLA typing at high resolution for the HLA loci (-A, -B, -C, -DRB1, -DQB1). Donor and recipient should share at least 5/10 HLA loci
  • HAPLOIDENTICAL DONOR: Age ≥ 18 years
  • HAPLOIDENTICAL DONOR: Weight ≥ 40 kg
  • HAPLOIDENTICAL DONOR: Donor must meet the selection criteria as defined by the Foundation of the Accreditation of Cell Therapy (FACT) and will be screened per the American Association of Blood Banks (AABB) guidelines
  • HAPLOIDENTICAL DONOR: In case of more available haploidentical donors, selection criteria should include, in this order:

    • For cytomegalovirus (CMV) seronegative recipients, a CMV seronegative donor
    • Red blood cell compatibility

      • Red blood cell (RBC) cross match compatible
      • Minor ABO incompatibility
      • Major ABO incompatibility

Exclusion criteria

Exclusion Criteria:

  • Active central nervous system (CNS) disease
  • Concomitant illness associated with a likely survival of \< 1 year
  • Active systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with antimicrobials and/or controlled or stable. Patients with fever thought to be likely secondary to lymphoid are eligible
  • Known or to any study drug used in this trial
  • Pregnancy or lactation
  • Concurrent treatment with any other approved or anti-lymphoma agent at the time of starting conditioning
  • HAPLOIDENTICAL DONOR: Since detection of anti-donor-specific antibodies (anti-DSA) is associated with higher graft rejection rate, patients will be screened for anti-DSA pre-transplant. Patient with DSA mean fluorescent intensity (MFI) \< 5000 after desensitization treatment, will be considered eligible to participate in the study
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Treatment (pralatrexate, bendamustine, TBI, PBSC HCT)

    Patients receive pralatrexate IV over 3-5 minutes on day -6, bendamustine IV over 60 minutes on days -5, -4, and -3, and TBI on day -1 or 0. Patients then undergo PBSC HCT on day 0. Patients also undergo ECHO or MUGA and lumbar puncture during screening, PET-CT, MRI, bone marrow biopsy/aspiration, and blood sample collection throughout the study. In addition, patients may undergo chest X-rays as clinically indicated.

    Drug: Bendamustine · Drug: Pralatrexate · Procedure: Bone Marrow Aspiration · Procedure: Bone Marrow Biopsy · Procedure: Chest Radiography · Procedure: Computed Tomography · Procedure: Echocardiography Test · Procedure: Lumbar Puncture · Procedure: Magnetic Resonance Imaging · Procedure: Multigated Acquisition Scan · Procedure: Peripheral Blood Stem Cell Transplantation · Procedure: Positron Emission Tomography · Other: Questionnaire Administration · Radiation: Total-Body Irradiation · Procedure: Biospecimen Collection

Interventions

  • Given IV

    Also known as: SDX 105, SDX-105, SDX105

  • Given IV

    Also known as: 10-propargyl-10-deazaaminopterin, Difolta, Folotyn, PDX

  • ProcedureBone Marrow Aspiration

    Undergo bone marrow biopsy/aspiration

  • ProcedureBone Marrow Biopsy

    Undergo bone marrow biopsy/aspiration

    Also known as: Biopsy of Bone Marrow, Biopsy, Bone Marrow

  • ProcedureChest Radiography

    Undergo chest X-rays

    Also known as: Chest X-ray

  • ProcedureComputed Tomography

    Undergo PET-CT

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • ProcedureEchocardiography Test

    Undergo ECHO

    Also known as: EC, Echocardiography

  • ProcedureLumbar Puncture

    Undergo lumbar puncture

    Also known as: LP, Spinal Tap

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

  • ProcedureMultigated Acquisition Scan

    Undergo MUGA

    Also known as: Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning

  • ProcedurePeripheral Blood Stem Cell Transplantation

    Undergo PBSC HCT

    Also known as: PBPC transplantation, PBSCT, Peripheral Blood, Peripheral Blood Progenitor Cell Transplantation, PERIPHERAL BLOOD STEM CELL TRANSPLANT, Peripheral Stem Cell Support, Peripheral Stem Cell Transplant, Peripheral Stem Cell Transplantation

  • ProcedurePositron Emission Tomography

    Undergo PET-CT

    Also known as: Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT

  • OtherQuestionnaire Administration

    Ancillary studies

  • RadiationTotal-Body Irradiation

    Undergo TBI

    Also known as: SCT_TBI, TBI, Total Body Irradiation, Whole Body, Whole Body Irradiation, Whole-Body Irradiation

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

06

What researchers measure

Primary outcomes

  1. Incidence and severity of treatment-emergent adverse events and treatment-emergent serious adverse events (Phase 1)

    In addition, clinically significant laboratory abnormalities, changes in vital signs, and changes in physical examination following allogeneic hematopoietic cell transplantation (allo-HCT). Will be graded according to Common Terminology Criteria for Adverse Events version 5.0. Will be summarized by grades and put in different tables by dose.

    Time frame: From pralatrexate dosing on day -6 to 28 days post-transplant

  2. Proportion of enrolled patients with T-cell non-Hodgkin lymphoma who successfully proceed to allogeneic-hematopoietic cell transplant (HCT) (Phase 2)

    Will compare it with the historical rate of 31%.

    Time frame: Up to 2 years post-transplant

Secondary outcomes

  1. Non-relapse mortality (NRM) (Phase 1)

    Time frame: Up to day 100 post-transplant

  2. Incidence and severity of grade II-IV acute graft-versus-host disease (GVHD) (Phase 2)

    Group comparisons will be performed using Gray's test, and multivariable analyses will be conducted using cause-specific Cox model to assess the effect of covariates. The cumulative incidence of acute will be estimated using the cumulative incidence function.

    Time frame: Up to day 100 post-transplant

  3. Incidence and severity of grade III-IV acute GVHD (Phase 2)

    Group comparisons will be performed using Gray's test, and multivariable analyses will be conducted using cause-specific Cox model to assess the effect of covariates. The cumulative incidence of acute will be estimated using the cumulative incidence function.

    Time frame: Up to day 100 post-transplant

  4. Incidence and severity of chronic GVHD requiring systemic immunosuppressive therapy (Phase 2)

    Group comparisons will be performed using Gray's test, and multivariable analyses will be conducted using cause-specific Cox model to assess the effect of covariates. Group comparisons will be performed using Gray's test, and multivariable analyses will be conducted using cause-specific Cox model to assess the effect of covariates. The cumulative incidence will be estimated using the cumulative incidence function.

    Time frame: At 1 year post-transplant

  5. Disease response rate (Phase 2)

    Proportion and counts will be calculated with an exact 95% confidence intervals.

    Time frame: At day 100 post-transplant

  6. Duration of remission from response until documented relapse or progression (Phase 2)

    Time frame: From response until documented relapse or progression, per disease-specific response criteria up to 2 years post-transplant

  7. Rates of donor chimerism ≥ 90% in peripheral blood CD3+ and CD33+ cell lines

    Proportion and counts will be calculated with an exact 95% confidence intervals. Donor chimerism will be summarized by the observed levels and levels categorized as ≥ 95%, 50% - 94%, 5% - 49%, or \< 5%.

    Time frame: Up to day 80 post-transplant

  8. Disease-free survival (Phase 2)

    Will be defined as the proportion of patients who are alive and free of disease. The Kaplan-Meier method will be used to estimate the median with 95% confidence intervals. Log-rank test will be used for group comparison. Proportion and counts will be calculated with an exact 95% confidence intervals.

    Time frame: From day 0 (date of graft infusion) to the first of: Relapse/progression of the underlying disease, or death from any cause, assessed up to 1 year post-transplant

  9. NRM (Phase 2)

    Time frame: Up to day 100 post-transplant

  10. Overall survival (Phase 2)

    The Kaplan-Meier method will be used to estimate the median with 95% confidence intervals. Log-rank test will be used for group comparison.

    Time frame: Up to 2 years post-transplant

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Sep 2030, 53 months after the start.

Of 29 phase 1/2 interventional studies under Lymphoma, T-Cell, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 92. This study's planned 53 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2025
First posted
Nov 10, 2025
StartActual
Apr 27, 2026
Primary completionEst.
Sep 30, 2030
CompletionEst.
Nov 15, 2030
Last update
May 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07225985
Responsible party
Sponsor
First posted
Nov 10, 2025
Start date
Apr 27, 2026
Primary completion
Sep 30, 2030 (estimated)
Completion
Nov 15, 2030 (estimated)
Last update
May 11, 2026

Study contacts

Lorenzo Iovino, MD, PhD
Contact
liovino@fredhutch.org
206-667-4475
Lorenzo Iovino, MD, PhD
principal investigator · Fred Hutch/University of Washington Cancer Consortium

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bendamustine · Pralatrexate

Start the discussion